Knight Therapeutics Inc (TSE:GUD) Director Robert Nathaniel Lande purchased 20,000 shares of the business’s stock in a transaction dated Thursday, July 11th. The shares were purchased at an average price of C$7.52 per share, for a total transaction of C$150,300.00. Following the purchase, the director now owns 45,392 shares of the company’s stock, valued at approximately C$341,120.88.
Shares of Knight Therapeutics stock opened at C$7.48 on Thursday. The stock has a market capitalization of $1.07 billion and a price-to-earnings ratio of 47.95. The company has a debt-to-equity ratio of 0.10, a quick ratio of 31.73 and a current ratio of 32.29. Knight Therapeutics Inc has a 12 month low of C$7.10 and a 12 month high of C$8.81. The company’s fifty day moving average price is C$7.57.
Knight Therapeutics (TSE:GUD) last announced its quarterly earnings results on Thursday, May 9th. The company reported C$0.04 EPS for the quarter, beating the consensus estimate of C$0.03 by C$0.01. The firm had revenue of C$2.96 million for the quarter, compared to analysts’ expectations of C$3.06 million. As a group, research analysts forecast that Knight Therapeutics Inc will post 0.15 earnings per share for the current year.
Knight Therapeutics Company Profile
Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.
Featured Article: What does a bar chart mean for investors?
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.